1. Scrip

NICE Reassessing Old CDF Drugs On Value-For-Money Basis – Some Fail

 
• By Sten Stovall

NICE has begun the new HTA appraisal process for Britain’s remodeled Cancer Drugs Fund and has so far provisionally rejected three of the 35 drugs contained in the old CDF on cost-effectiveness grounds; two others got a thumbs up after their manufacturers offered further price cuts.

SC1608_Assessment-magnifying glass_1200x675

The National Institute for Health and Care Excellence is assessing 35 drugs contained in the old Cancer Drug Fund for their cost effectiveness and is displaying characteristic hard-nosed resolve about whether licensed medicines currently there should remain in it, should be recommended for routine commissioning, or cannot be recommended at all. NICE has so far provisionally rejected three drugs and okayed two out of a list of 35.

The independent agency is responsible for a "managed access" fund launched by NHS England in the end of July, with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By Joseph Haas

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.